Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079757 | 1.00 | CYP19A1 (0.44) | CYP19A1ALDH1A1SMN1; SMN2NPSR1FFAR3 | |
| SCHEMBL25383029 | 1.00 | CYP19A1 (0.44) | CYP19A1ALDH1A1SMN1; SMN2NPSR1FFAR3 | |
| SCHEMBL12986568 | 0.97 | CYP19A1 (0.42) | CYP19A1NPSR1FFAR3SCN1ASCN2A | |
| SCHEMBL17847300 | 0.90 | CYP19A1 (0.42) | CYP19A1ALDH1A1SMN1; SMN2NPSR1SCN1A | |
| SCHEMBL9500027 | 0.90 | CYP19A1 (0.42) | CYP19A1ALDH1A1SMN1; SMN2NPSR1SCN1A | |
| SCHEMBL30599563 | 0.88 | CYP19A1 (0.41) | CYP19A1ALDH1A1SMN1; SMN2NPSR1MEN1 | |
| SCHEMBL30527929 | 0.88 | CYP19A1 (0.41) | CYP19A1ALDH1A1SMN1; SMN2NPSR1MEN1 | |
| SCHEMBL1439339 | 0.88 | CYP19A1 (0.41) | CYP19A1ALDH1A1SMN1; SMN2NPSR1MEN1 | |
| SCHEMBL1439337 | 0.86 | CYP19A1 (0.40) | CYP19A1 | |
| SCHEMBL21514964 | 0.86 | CYP19A1 (0.40) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| EP-4692252-A1 | FUNCTIONAL PARTICLE DISPERSION | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20250084050-A1 | FRAGRANCE COMPOSITION | KAO CORPORATION (JP) | 2025-03-13 | — | — | US | disclosed |
| CN-118786128-A | Compounds and methods for treating viral infections | 吉利德科学公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118451170-A | Cleaning agent composition | 花王株式会社 | 2024-08-06 | — | — | CN | disclosed |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-05-09 | — | — | US | disclosed |
| CN-113039259-B | Transparent liquid composition | 株式会社资生堂 | 2024-04-26 | — | — | CN | disclosed |
| EP-4353327-A1 | PERFUME COMPOSITION | Kao Corporation (JP) | 2024-04-17 | — | — | EP | disclosed |
| EP-4320128-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117545827-A | Perfume composition | 花王株式会社 | 2024-02-09 | — | — | CN | disclosed |
| EP-2857482-A1 | PERFUME COMPOSITION | Kao Corporation (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8961946-B2 | Hair processing agent and method for permanent waving hair | SHOWA DENKO K.K. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20140221269-A1 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-08-07 | — | — | US | disclosed |
| EP-1698726-B1 | Fiber product treating agent | KAO CORP (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-7381345-B2 | Fiber product treating agent | KAO CORPORATION (JP) | 2008-06-03 | — | — | US | disclosed |
| US-20080085251-A1 | even at a neutral to weakly acidic pH; a lactone or lactam having a mercapto group; with thioglycolic acid, thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine; | RESONAC CORPORATION (JP) | 2008-04-10 | — | — | US | disclosed |
| EP-1827370-A1 | HAIR PROCESSING AGENT AND METHOD FOR PERMANENT WAVING HAIR | Showa Denko K.K. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060198808-A1 | Increasing the longevity of perfume contained in a fiber product treating agent by adding a long-chain alkyl- or alkenylamine, amine salt or quaternary ammonium salt in which the chain may be interrupted by a secondary amide group: N-[3-(dimethylamino)propyl]- stearamide or behenamide | KAO CORPORATION (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-1698726-A1 | Fiber product treating agent | Kao Corporation (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2006068276-A1 | HAIR PROCESSING AGENT AND METHOD FOR PERMANENT WAVING HAIR | SHOWA DENKO K.K. (JP) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | CYP19A1 4351/4885ALDH1A1 1784/4885SMN1; SMN2 1064/4885 |
| US-20250084050-A1 | FRAGRANCE COMPOSITION | TRPA1, C5, CBR1 | CYP19A1 164/4885ALDH1A1 447/4885SMN1; SMN2 3929/4885 |
| US-20060198808-A1 | Increasing the longevity of perfume contained in a fiber product treating agent by adding a long-chain alkyl- or alkenylamine, amine salt or quaternary ammonium salt in which the chain may be interrupted by a secondary amide group: N-[3-(dimethylamino)propyl]- stearamide or behenamide | CERT1, FAAH, FAAH2 | CYP19A1 1437/4885ALDH1A1 2799/4885SMN1; SMN2 262/4885 |
| US-20080085251-A1 | even at a neutral to weakly acidic pH; a lactone or lactam having a mercapto group; with thioglycolic acid, thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine; | TST, CYSLTR1, CYSLTR2 | CYP19A1 579/4885ALDH1A1 672/4885SMN1; SMN2 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.